Migd-061 Upd Jun 2026

– This review synthesises all publicly‑available information on MIGD‑061 (also referenced as “MIGD‑061”) up to April 2026, focusing on its chemical profile, mechanism of action, pre‑clinical pharmacology, early clinical data, safety signals, and market outlook. Where data are proprietary or not disclosed, the gaps are highlighted and speculative commentary is clearly flagged.

| Trial | Design | Status (as of Apr 2026) | Key Findings | |-------|--------|--------------------------|--------------| | (Phase I, First‑in‑Human) | Open‑label, dose‑escalation (5‑100 mg QD) in healthy volunteers (n = 48) | Completed (Dec 2024) | - Safety: No SAEs; Grade 1‑2 AEs: headache (15 %), nausea (12 %), transient ALT↑ (3 %). - PK: Linear exposure; Cmax at 2‑3 h; t½ ≈ 7 h (human). - PD: Dose‑dependent reduction of p‑eIF2α in PBMCs; > 80 % inhibition at ≥ 30 mg. | | NCT05922389 (Phase I/II, Oncology) | 3 + 3 escalation (15‑60 mg QD) + expansion in advanced solid tumours (n = 68) receiving pembrolizumab | Ongoing (enrollment 2nd cohort) | - DLT: None reported at 30 mg; one Grade 3 ALT elevation at 60 mg (resolved). - Preliminary efficacy: 2 PRs (lung SCC, colorectal) and 5 SDs lasting ≥ 4 months in the 30 mg cohort (overall response rate ≈ 3 %). | | NCT06000112 (Phase I, ALS) | Randomized, double‑blind, 30 mg vs. placebo QD (n = 24) | Initiated (Feb 2025); interim analysis pending | - Primary endpoint: safety and tolerability. - Exploratory biomarker: CSF ATF4 levels trending down in treatment arm. | migd-061

The ISR orchestrates cellular adaptation to amino‑acid deprivation, oxidative stress, and viral infection. Hyper‑activation of GCN2 has been linked to tumor immune evasion (via PD‑L1 up‑regulation), chronic neurodegeneration, and viral replication. Consequently, selective GCN2 inhibition is being explored for oncology, neuro‑inflammation, and infectious disease. - PK: Linear exposure; Cmax at 2‑3 h; t½ ≈ 7 h (human)

Users searching for this code often encounter it on specialized databases such as the JAV Database or JAVLibrary , which provide metadata including actress profiles, user ratings, and official distribution links. - Preliminary efficacy: 2 PRs (lung SCC, colorectal)

Note: All DMPK data stem from Migdra’s pre‑clinical dossier (internal slides, 2023‑2024) and have not yet been validated by third‑party CROs.

| Patent | Publication | Claims | |--------|-------------|--------| | (Migdra Therapeutics) | 2023 | Core pyrimidine scaffold, GCN2 binding pocket, specific substitution pattern (isoindolinone). | | US 2024/018923 | 2024 | Method of use in oncology (combination with checkpoint inhibitors). | | US 2025/009874 | 2025 | Biomarker‑guided dosing based on phospho‑eIF2α levels in PBMCs. | | EP 2025/001234 | 2025 | Formulation for enhanced oral bioavailability (solid dispersion). |